Related coverage linked through entity extraction aliases.
Mar 19, 2026
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
Mar 17, 2026
ACT Capital Management invested $7.25 million in Viking Therapeutics as the company advances its obesity drug candidate VK2735 into Phase 3 trials. India's drug regulator warned pharmaceutical companies against direct or surrogate advertising of weight-loss medicines, while South Korean drugmakers target year-end commercialization of domestically developed obesity treatments.
Mar 16, 2026
Eli Lilly announced positive Phase 3 results for EBGLYSS in pediatric atopic dermatitis, orforglipron in diabetes showing superiority over Rybelsus, and Retevmo in early-stage lung cancer, expanding potential indications across its portfolio.
Mar 10, 2026
Natco Pharma has received CDSCO approval to manufacture and market generic semaglutide injection in India, with a planned March 2026 launch. Eris Lifesciences will commercialize the product through a partnership.
Mar 10, 2026
Total spending on direct-to-consumer prescription drug advertising reached $9 billion in 2024, prompting renewed debate over whether such marketing should be legal. The U.S. and New Zealand remain the only developed nations allowing the practice.
Mar 09, 2026
Eli Lilly's weight-loss drug Mounjaro fueled sevenfold sales growth in Brazil and doubled sales in India within months of launch, as the company commits $1 billion to make India a global export hub for its supply chain.
Mar 09, 2026
Novo Nordisk dismissed its patent infringement lawsuit against Hims & Hers after the companies reached an agreement to sell branded Wegovy and Ozempic through the Hims platform. The settlement ends a dispute that began when Hims planned to offer a cheaper off-brand version of Wegovy.
Mar 08, 2026
Pfizer is applying lessons from its Viagra launch to introduce its first obesity treatment, a monthly injection acquired from Metsera. The company aims to leverage past experience with sensitive health topics as it enters the competitive obesity market.
Mar 08, 2026
Novo Nordisk struggles against Eli Lilly in the weight loss market as CagriSema underperforms Zepbound, though new candidate UBT251 shows promise with 19.7% weight loss in 24 weeks. The company expects sales to decline in 2026 despite oral Wegovy's success.
Mar 07, 2026
Incyte received a Complete Response Letter from the FDA for Zynyz in lung cancer due to third-party manufacturing issues, while the EMA recommended approval for the drug in anal cancer treatment based on Phase 3 trial data.
Mar 06, 2026
New research links GLP-1 drugs like Ozempic to increased scurvy risk through appetite suppression and poor nutrition. University of Florida researchers are testing a GLP-1 implant for obese cats as feline obesity affects nearly 60% of US cats.
Mar 06, 2026
New research reveals how GLP-1 receptor agonists promote pancreatic health through gene expression changes and interact bidirectionally with gut microbiome, while real-world users report unexpected lifestyle changes alongside weight loss.
Mar 04, 2026
Novo Nordisk filed a patent infringement lawsuit against Hims & Hers over compounded versions of Wegovy. The legal action follows the telehealth company's announcement of a $49 oral pill, which was withdrawn after FDA warnings.
Mar 04, 2026
Novo Nordisk announced a $506 million investment to expand its Athlone, Ireland manufacturing facility for oral GLP-1 drugs, following strong early uptake of Wegovy weight loss pills in the US market.
Mar 04, 2026
Scholar Rock plans to resubmit its biologics license application for apitegromab in spinal muscular atrophy following FDA reinspection of the Catalent Indiana fill-finish facility, with a U.S. launch anticipated in 2026.
Mar 02, 2026
The pharmaceutical industry is experiencing recovery driven by innovation in drug development, aggressive M&A activity, and expansion of drug development services. The sector faces both opportunities and headwinds including pipeline setbacks and regulatory pressures.
Mar 02, 2026
Australian regulators confirmed counterfeit GLP-1 products contain no active ingredients, while U.S. authorities escalate enforcement against compounded weight-loss drugs as Novo Nordisk sues telehealth company Hims & Hers.
Feb 28, 2026
Oral semaglutide reduced heart failure events by 22% in Type 2 diabetes patients with existing heart failure in a trial of nearly 9,650 adults, with particular benefit in HFpEF cases.
Feb 27, 2026
Abbott India will commercialize semaglutide, the diabetes drug behind Ozempic, under the brand name Extensior in India following a partnership with Novo Nordisk. The launch targets India's growing diabetes population of over 100 million people.
Feb 25, 2026
Novo Nordisk announced it will reduce list prices of Wegovy, Ozempic, and Rybelsus by 35% to 50% to $675 monthly starting in 2027, aiming to regain market share from rival Eli Lilly and improve access for high-deductible patients.
